News & Events
[ Press Release ]
-
ARCALIS Signs a Memorandum of Understanding with Fukushima Medical University and Fukushima Translational Research Foundation for Comprehensive Collaboration on Research, Development and Manufacturing of mRNA Pharmaceuticals and Vaccines
-
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
-
ARCALIS Signs Collaboration Agreement with the National Cancer Center Japan for Research, Development and Manufacturing of mRNA Pharmaceuticals
-
The Construction Plan of mRNA Therapeutics Manufacturing, Technology Development Facility has been Selected for the METI Subsidy Programs
-
Notice of ARCALIS’ Head Office Relocation
-
Notice of Completion of New mRNA Drug Substance Plant
-
ARCALIS Renews the Corporate Logo design
-
Notice Concerning Change of Representative Directors
-
ARCALIS and Hitachi Enter Joint Research Agreement on mRNA Sequence Design Technology
-
Arcturus Therapeutics Announces Strategic collaboration with CSL
-
Construction plan of mRNA therapeutics and vaccine production facility has been adopted for “Biopharmaceutical Production Base Development Project for Strengthening the Vaccine Production System” by the Ministry of Economy, Trade and Industry
-
ARCALIS and Axcelead DDP Announce Collaboration to Provide Integrated Drug Discovery Support Service for mRNA Therapeutics
-
Axcelead Decided to Build an mRNA Drug Manufacturing Plant in Minamisoma City, Fukushima Prefecture
-
Axcelead Launches ARCALIS, a Joint Venture to Manufacture mRNA Therapeutics